EGFR and hypertensive disorder: Thus, it might be justifiable to reconsider the continuation of bevacizumab at the first response evaluation, and cessation in the absence of HTN may be wise if the patient has poor tolerability, if economical restraints for the use of the drug exist, or if alternative therapies are available, for example, EGFR inhibitors.